Prognostic value of T-1 cell numbers prior to allogeneic stem cell transplantation in patients with severe graft-versus-host disease

Bone Marrow Transplantation

Volumn 35, Issue 7, 2005, Pages 691-697

  Banning, U ^a   Lange, T ^a   Krahl, R ^a   Mauz Korholz C ^a   Krutmann, J ^b   Niederwieser, D ^a   Korholz D ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Allogeneic transplantation; GvHD; Prognostic value

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; IMATINIB; INTERFERON; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE SEVERITY; FISHER EXACT TEST; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WHOLE BODY RADIATION;

ADULT; CYTOKINES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE COUNT; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 17144362900     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704874     Document Type: Article

References (40)

1. Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13: 135-139.
2. Borgmann A, von Stackelberg A, Hartmann R et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835-3839.
3. Yumura-Yagi K, Hara J, Horibe K et al. Outcome after relapse in childhood acute lymphoblastic leukemia. Int J Hematol 2002; 76: 61-68.
4. Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol 2003; 40: 59-71.
5. Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 2003; 44: 23-28.
6. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant 2003; 32 73-77.
7. Daly A, McAfee S, Dey B et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9: 373-382.
8. Bonig H, Schneider DT, Sprock I et al. Sepsis' and multi-organ failure: predictors of poor outcome after hematopoietic stem cell transplantation in children. Bone Marrow Transplant 2000; 25 (Suppl. 2): S32-S34.
9. Pastores SM, Papadopoulos E, van den Brink M et al. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplant 2002; 30: 131-134.
10. Martino R, Giralt S, Caballero MD et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lympho-blastic leukemia: a feasibility study. Haematologica 2003; 88: 555-560.
11. Georges GE, Maris M, Sandmaier BM et al. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol 2002; 76 (Suppl. 1): 184-189.
12. Cavet J, Middleton PG, Segall M et al. Recipient tumor necrosis factor-α and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3914-3946.
13. Holler E, Roncarolo MG, Hintermeier-Knabe R et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 237-241.
14. Sykes M. Novel approaches to the control of graft versus host disease. Curr Opin Immunol 1993; 5: 774-781.
15. Rus V, Svetic A, Nguyen P et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 1995; 155: 2396-3406.
16. Love KS, Lakshmanan RR, Butterfield JH, Fox CC. IFN-gamma-stimulated enhancement of MHC class II antigen expression by the human mast cell line HMC-1. Cell Immunol 1996; 170: 85-90.
17. Niederwieser D, Aubock J, Troppmair J et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 1988; 140: 2556-2564.
18. Banning U, Korholz D. Intracellular detection of T-cell cytokines. Differentiation of TH1 and TH2 cells. In: Kiess W, Korholz D (eds). Methods in Molecular Biology. Humana Press: Totowa, New Jersey, Vol 215, 2003, pp 15-22.
19. Urbano-Ispizua A, Rozman C, Pimentel P et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002; 100: 724-727.
20. Kollman C, Howe CW, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-2051.
21. Keever-Taylor CA, Bredeson C, Loberiza FR et al. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001; 7: 620-630.
22. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259-277.
23. Banna GL, Aversa S, Sileni VC et al. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly non-myeloablative and reduced intensity conditioning regimens. Crit Rev Oncol 2004; 51: 171-189.
24. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
25. Eskdale J, Gallagher G, Verweij CL et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-9470.
26. Bejarano MT, de Waal Malefyt R, Abrams JS et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1992; 4: 1389-1397.
27. Korholz D, Banning U, Bonig H et al. The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses. Blood 1997; 90: 4513-4521.
28. Niederwieser D, Herold M, Woloszczuk W et al. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620-625.
29. De Maeyer E, De Maeyer-Guignard J. Interferons. In: Thomson A (ed.). The Cytokine Handbook. Academic press: San Diego, 1998, pp, 491-516.
30. Weiden PL, Doney K, Storb R, Thomas ED. Anti-human thymocyte globulin for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow graft. Transplant Proc 1978; 10 213-216.
31. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomised trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-8.
32. Deeg HJ, Loughran Jr TP, Storb R et al. Treatment of acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40: 162-166.
33. Dugan MJ, DeFor TE, Steinbuch M et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Ann Hematol 1997; 75: 41-46.
34. Cragg L, Blazar BR, Defor T et al. A randomised trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 441-447.
35. Remberger M, Aschan J, Barkholt L et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplantation 2001; 15: 147-153.
36. Bonig H, Korholz D, Lex C et al. Monocyte deactivation and ist reversal in a patient with chemotherapy-induced leukopenia and severe systemic infection. Med Pediatr Oncol 2000; 34: 39-42.
37. Wong GH, Clark-Lewis I, McKimm-Breschkin L et al. Interferon-gamma induces enhanced expression of Ia and H-2 antigens on b lymphoid, macrophage, and myeloid cell lines. J Immunol 1983; 131: 788-793.
38. Ito T, Amakawa R, Inaba M et al. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001; 166: 2961-2969.
39. Anderson BE, McNiff JM, Jain D et al. Distinct roles for donor- and host-derived antigen presenting cells and costimulatory molecules in murine chronic graft versus host disease: requirements depend on target organ. Blood First Edition Paper, prepublished online November 2, 2004, DOI 10. 1182/blood-2004-08-3032.
40. Storkus WJ, Tahara H, Lotze MT. Interleukin-12. In: Thomson AW (ed.). The Cytokine Handbook. Academic Press: San Diego, CA, 1998, pp 391-426.